Shire's dry eye drug lifitegrast granted speedy review
This article was originally published in Scrip
Executive Summary
The FDA has granted a priority review to Shire's new drug application for lifitegrast, an investigational treatment for dry eye disease in adults, and has set 25 October as the Prescription Drug User Fee Act action date.